To evaluate how the activation of the NAD+ salvage pathway affects tumor growth, we evaluated the cell viability of the NAMPT inhibitor FK866 in combination with CANA to suppress the NAMPT-NAD+-SIRT1 pathway. Here, SIRT1 is linked to neoplasm.